Northwestern Memorial Hospital, Northwestern University, 676 N St Clair St, Suite 800, Chicago, IL, 60611, USA.
Skeletal Radiol. 2024 Jun;53(6):1145-1152. doi: 10.1007/s00256-023-04548-5. Epub 2023 Dec 19.
Image-guided spine injections are an important tool in the management of patients with a variety of spinal pathologies. Our practice offers radiologist-performed fluoroscopy-guided interlaminar cervical epidural steroid injection (ESI) routinely performed in the outpatient setting. The purpose of this study was to evaluate clinical outcomes and improvement in pain scores after radiologist-performed cervical ESI.
An institutional database was used to retrospectively identify cervical injections performed between October 2016 and October 2022. All injections were performed at the C7-T1 level utilizing 1.0 mL of 10 mg/mL dexamethasone without epidural anesthetic. The Numerical Rating Scale (NRS) was used to assess pain improvement. Cervical MRI was reviewed to assess pre-injection cervical disease severity. Patient charts were reviewed for any post-injection complications.
A total of 251 cervical injections in 186 patients met our inclusion criteria with mean clinical follow up of 28.5 months (range 0.2 - 73.0 months). No patients experienced any major complications after injection. Post-injection pain scores were available for 218 of 251 injections (86.9%) with mean follow-up of 11.8 days (range 6 - 57 days). There was a significant improvement in pain scores from a mean pre-injection NRS score of 5.2/10 to 3.0/10 (p < .0001). 117 patients (53.7%) reported ≥ 50% improvement after injection. Patients who had prior injection were more likely to report ≥ 50% pain improvement after subsequent injection (p = .012).
Radiologist-performed fluoroscopy-guided interlaminar cervical ESI at the C7-T1 level is a safe and effective tool in the management of patients with cervical pathology.
影像引导下脊柱注射是治疗各种脊柱病变患者的重要工具。我们的常规实践是在门诊环境下由放射科医生进行经皮透视引导下的颈椎硬膜外类固醇注射(ESI)。本研究的目的是评估放射科医生进行颈椎 ESI 后的临床结果和疼痛评分改善情况。
使用机构数据库回顾性确定 2016 年 10 月至 2022 年 10 月期间进行的颈椎注射。所有注射均在 C7-T1 水平进行,使用 1.0 mL 10mg/mL 地塞米松,不使用硬膜外麻醉剂。使用数字评分量表(NRS)评估疼痛改善情况。颈椎 MRI 用于评估注射前颈椎疾病的严重程度。患者病历用于评估任何注射后的并发症。
共纳入 186 例患者的 251 次颈椎注射,平均临床随访时间为 28.5 个月(范围 0.2-73.0 个月)。无患者在注射后发生任何重大并发症。251 次注射中有 218 次(86.9%)可获得注射后疼痛评分,平均随访时间为 11.8 天(范围 6-57 天)。与注射前的 NRS 评分 5.2/10 相比,疼痛评分有显著改善(p < .0001),平均降至 3.0/10。117 例患者(53.7%)报告注射后疼痛改善 ≥ 50%。与首次注射后报告疼痛改善 ≥ 50%的患者相比,先前接受过注射的患者更有可能在随后的注射后报告疼痛改善 ≥ 50%(p = .012)。
在 C7-T1 水平进行经皮透视引导下的颈椎硬膜外间隙注射是治疗颈椎病变患者的一种安全有效的方法。